Skip to main content

Advertisement

SpringerLink
Log in

Comments on Kamimura et al.: significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients

  • Letter
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kamimura M, Nakamura Y, Ikegami S, Uchiyama S, Kato H, Taguchi A (2016) Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients. Osteoporos Int. doi:10.1007/s00198-016-3764-7

    PubMed  PubMed Central  Google Scholar 

  2. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis Foundation (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Dennis MB, Ian RR, Jane AC, Felicia C, Ping Chung L, Peter L, Kurt L, Steven RC, Trisha FH, Amitava M, Monique T, Paul Aftring R, Richard E (2006) Effects of continuing or stopping alendronate after 5 years of treatment. The fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296:2927–2938

    Article  Google Scholar 

  4. Dennis MB, Ian RR, Jane AC, Felicia C, Ping CL, Peter L, Kurt L, Steven RC, Trisha FH, Amitava M, Monique T, Paul Aftring R, Richard E (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res 30:934–944

    Article  Google Scholar 

  5. Ann VS, Douglas CB, Steven RC, Jane AC, Kristine EE, Lisa P, Robert BW, Marc CH, Adrianne CF, Antonio L, Dennis M Black1, for the FLEX Research Group (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture:the FLEX trial. J Bone Miner Res 25:976–982

    Article  Google Scholar 

  6. Prashanth Peddi1, Maria A L-Olivo1, Gregory F Pratt2, Maria E S-Almazor1 (2013) Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev 39:97–104

    Article  Google Scholar 

  7. Elizabeth S, David B, Bo A, Robert AA, Thomas DB, Angela MC, Felicia C, Jeffrey RC, Richard D, David WD, Peter RE, Thomas AE, Harry KG, Piet G, Klaus K, Joseph ML, Fergus MK, Ross MK, Alvin N, Jeri N, Regis O’K, Socrates P, Tet SH, Marjolein CHVDM, Robert SW, Michael PW (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Metabolism & Endocrinology, The 2nd Xiangya Hospital, Central South University, Renmin road 139#, Changsha, Hunan, 410011, People’s Republic of China

    S. J. Fu & Z. F. Sheng

  2. National Clinical Research Center for Metabolic Diseases, The 2nd Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China

    S. J. Fu & Z. F. Sheng

  3. Institute of Metabolism and Endocrinology, The 2nd Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China

    S. J. Fu & Z. F. Sheng

  4. Department of Endocrinology, Hannan Province Nongken Sanya Hospital, Sanya, Haina, 572000, China

    S. J. Fu

Authors
  1. S. J. Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. F. Sheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Z. F. Sheng.

Ethics declarations

Conflicts of interest

None.

Additional information

A response to these comments can be found at doi: 10.1007/s00198–017–3923-5.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fu, S.J., Sheng, Z.F. Comments on Kamimura et al.: significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients. Osteoporos Int 28, 1755–1756 (2017). https://doi.org/10.1007/s00198-016-3867-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-016-3867-1

Keywords

Search

Navigation